EP
TGTX icon

Essential Partners’s TG Therapeutics TGTX Stock Holding History

Essential Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.86K Buy
143
+113
+377% +$4.63K ﹤0.01% 1326
2026
Q1 		$997 Buy
30
+18
+150% +$536 ﹤0.01% 2249
2025
Q4 		$358 Sell
12
-1
-8% -$33 ﹤0.01% 2303
2025
Q3 		$470 Buy
+13
New +$428 ﹤0.01% 2220

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Essential Partners's TGTX Position: Q2 2026 in Review

Essential Partners increased its TG Therapeutics (TGTX) stake by 377% in Q2 2026, buying an estimated $4.63K and bringing the position to 143 shares worth $7.86K. The position accounts for ﹤0.01% of the portfolio, ranked #1326.

Essential Partners first reported a position in TGTX in Q3 2025 and has held it in 4 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Essential Partners held 143 shares of TG Therapeutics worth $7.86K as of Q2 2026.
  • Essential Partners bought 113 TG Therapeutics shares in Q2 2026, an estimated $4.63K.
  • TG Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1326 holding.
  • Essential Partners first reported a position in TG Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.